PMID- 31099200
OWN - NLM
STAT- MEDLINE
DCOM- 20200406
LR  - 20200408
IS  - 2093-5978 (Electronic)
IS  - 2093-596X (Print)
IS  - 2093-596X (Linking)
VI  - 34
IP  - 2
DP  - 2019 Jun
TI  - The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose 
      Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with 
      Type 2 Diabetes.
PG  - 106-116
LID - 10.3803/EnM.2019.34.2.106 [doi]
AB  - The prevalence of type 2 diabetes mellitus (T2DM), which is associated with 
      cardiovascular morbidity and mortality, is increasing worldwide. Although there 
      have been advances in diabetes treatments that reduce microvascular complications 
      (nephropathy, neuropathy, retinopathy), many clinical studies have found that 
      conventional oral hypoglycemic agents and glucose control alone failed to reduce 
      cardiovascular disease. Thus, incretin-based therapies including glucagon-like 
      peptide 1 (GLP-1) receptor agonists (RAs) and sodium-glucose cotransporter 2 
      inhibitors (SGLT-2Is) represent a new area of research, and may serve as novel 
      therapeutics for treating hyperglycemia and modifying other cardiovascular risk 
      factors. Recently, it has been confirmed that several drugs in these classes, 
      including canagliflozin, empagliflozin, semaglutide, and liraglutide, are safe 
      and possess cardioprotective effects. We review the most recent cardiovascular 
      outcome trials on GLP-1RAs and SGLT-2Is, and discuss their implications for 
      treating patients with T2DM in terms of protective effects against cardiovascular 
      disease.
CI  - Copyright (c) 2019 Korean Endocrine Society.
FAU - Kim, Gwang Sil
AU  - Kim GS
AD  - Department of Internal Medicine, Inje University Sanggye Paik Hospital, Inje 
      University College of Medicine, Seoul, Korea.
AD  - Cardiovascular and Metabolic Disease Center (CMDC), Inje University, Busan, 
      Korea.
FAU - Park, Joong Hyun
AU  - Park JH
AD  - Department of Neurology, Inje University Sanggye Paik Hospital, Inje University 
      College of Medicine, Seoul, Korea.
FAU - Won, Jong Chul
AU  - Won JC
AUID- ORCID: 0000-0002-2219-4083
AD  - Department of Internal Medicine, Inje University Sanggye Paik Hospital, Inje 
      University College of Medicine, Seoul, Korea.
AD  - Cardiovascular and Metabolic Disease Center (CMDC), Inje University, Busan, 
      Korea. drwonjc@gmail.com.
LA  - eng
GR  - 2010-0020224/NRF/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190509
PL  - Korea (South)
TA  - Endocrinol Metab (Seoul)
JT  - Endocrinology and metabolism (Seoul, Korea)
JID - 101554139
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Cardiovascular Diseases/complications/*drug therapy
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Sodium-Glucose Transporter 2 Inhibitors
PMC - PMC6599901
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Heart failure
OT  - Hypoglycemic agents
OT  - Myocardial ischemia
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2019/05/18 06:00
MHDA- 2020/04/09 06:00
PMCR- 2019/06/01
CRDT- 2019/05/18 06:00
PHST- 2019/01/15 00:00 [received]
PHST- 2019/02/25 00:00 [revised]
PHST- 2019/03/04 00:00 [accepted]
PHST- 2019/05/18 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
PHST- 2019/05/18 06:00 [entrez]
PHST- 2019/06/01 00:00 [pmc-release]
AID - 34.e3 [pii]
AID - 10.3803/EnM.2019.34.2.106 [doi]
PST - ppublish
SO  - Endocrinol Metab (Seoul). 2019 Jun;34(2):106-116. doi: 10.3803/EnM.2019.34.2.106. 
      Epub 2019 May 9.